Article information
Abstract
Objectives
Detection of mutations associated to nucleos(t)ide analogs and hepatitis B virus (HBV) genotyping are essential for monitoring treatment of HBV infection. We developed a multiplex polymerase chain reaction-ligase detection reaction (PCR-LDR) assay for the rapid detection of HBV genotypes and mutations associated with lamivudine, adefovir, and telbivudine resistance in HBV-infected patients.
MethodsHBV templates were amplified by PCR, followed by LDR and electrophoresis on a sequencer. The assay was evaluated using plasmids that contained wild-type or mutant HBV sequences and 216 clinical samples.
ResultsThe PCR-LDR assay and sequencing gave comparable results for 158 of the 216 samples (73.1%) with respect to mutation detection and genotyping. Complete agreement between the two methods was observed for all the samples (100%) at codon 180 and codon 204. Concordant results were observed for 99.4% of the 158 samples at codon 181 and 98.7% at codon 236. The genotyping results were completely concordant between the PCR-LDR assay and sequencing. The PCR-LDR assay could detect a proportion of 1% mutant plasmid in a background of wild-type plasmid.
ConclusionThe PCR-LDR assay is sensitive and specific for detection of HBV genotypes and drug resistance mutations, and could be helpful for decision making in the treatment of HBV infection.
Keywords:
hepatitis B
drug resistance
mutation
genotype
Full text is only aviable in PDF
References
[1.]
W. Alazawi, G.R. Foster.
Advances in the diagnosis and treatment of hepatitis B.
Curr Opin Infect Dis, 21 (2008), pp. 508-515
[2.]
J.H. Kao, N.H. Wu, P.J. Chen, et al.
Hepatitis B genotypes and the response to interferon therapy.
J Hepatol, 33 (2000), pp. 998-1002
[3.]
H.L. Janssen, M. van Zonneveld, H. Senturk, et al.
Pegylated interferon alfa-2b alone or in comination with lamivudine for HbeAg-positive chronic hepatitis B: a randomised trial.
Lancet, 365 (2005), pp. 123-129
[4.]
A.S. Lok, F. Zoulim, S. Locarnini.
Antiviral drug-resistant HBV: Standardization of nomenclature and assays and recommendations for management.
Hepatology, 46 (2007), pp. 254-265
[5.]
S.K. Fung, A.S. Lok.
Hepatitis B virus genotypes: do they play a role in the outcome of HBV infection?.
Hepatology, 40 (2004), pp. 790-792
[6.]
H. Norder, A.M. Courouce, P. Coursaget, et al.
Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes.
Intervirology, 47 (2004), pp. 289-309
[7.]
C.T. Wai, C.J. Chu, M. Hussain, et al.
HBV genotype B is associated with better response to interferon therapy in HBeAg (+) chronic hepatitis than genotype C.
Hepatology, 36 (2002), pp. 1425-1430
[8.]
A. Erhardt, D. Blondin, K. Hauck, et al.
Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D.
Gut, 54 (2005), pp. 1009-1013
[9.]
W.G. Cooksley.
Do we need to determine viral genotype in treating chronic hepatitis B?.
J Viral Hepat, 17 (2010), pp. 601-610
[10.]
P.R. Ferreira, S.D. Tenore.
Response predictors to treatment with pegylated interferon in chronic hepatitis B.
Braz J Infect Dis, 14 (2010), pp. 519-525
[11.]
A.W. Walsh, D.R. Langley, R.J. Colonno, et al.
Mechanistic characterization and molecular modeling of hepatitis B virus polymerase resistance to entecavir.
PloS One, 5 (2010), pp. e9195
[12.]
M.I. Allen, M. Deslauriers, C.W. Andrews, Lamivudine Clinical Investigation Group, et al.
Identification and characterization of mutations in hepatitis B virus resistant to lamivudine.
Hepatology, 27 (1998), pp. 1670-1677
[13.]
J. Gauthier, E.J. Bourne, M.W. Lutz, et al.
Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine.
J Infect Dis, 180 (1999), pp. 1757-1762
[14.]
T.T. Chang, C.L. Lai, R.N. Chien, et al.
Four years of lamivudine treatment in Chinese patients with chronic hepatitis B.
J Gastroenterol Hepatol, 19 (2004), pp. 1276-1282
[15.]
L. Stuyver, C. Van Geyt, S. De Gendt, et al.
Line probe assay for monitoring drug resistance in hepatitis B virus infected patients during antiviral therapy.
J Clin Microbiol, 38 (2000), pp. 702-707
[16.]
P. Marcellin, T.T. Chang, S.G. Lim, et al.
Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.
Hepatology, 48 (2008), pp. 750-758
[17.]
S.J. Hadziyannis, N.C. Tassopoulos, E.J. Heathcote, et al.
Longterm therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.
N Engl J Med, 352 (2005), pp. 2673-2681
[18.]
Y.S. Lee, D.J. Suh, Y.S. Lim, et al.
Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy.
Hepatology, 43 (2006), pp. 1385-1391
[19.]
X. Liang, S. Bi, W. Yang, et al.
Epidemiological serosurvey of hepatitis B in China – declining HBV prevalence due to hepatitis b vaccination.
Vaccine, 27 (2009), pp. 6550-6557
[20.]
S.D. Pas, R.A. de Man, E. Fries, et al.
The dynamics of mutations in the YMDD motif of the hepatitis B virus polymerase gene during and after lamivudine treatment as determined by reverse hybridization.
J Clin Virol, 25 (2002), pp. 63-71
[21.]
M. Hussain, S. Fung, E. Libbrecht, et al.
Sensitive line probe assay that simultaneously detects mutations conveying resistance to lamivudine and adefovir.
J Clin Microbiol, 44 (2006), pp. 1094-1097
[22.]
H.G. Niesters, F. Zoulim, C. Pichoud, et al.
Validation of the INNO- LiPA HBV DR assay (version 2) in Monitoring hepatitis B virus-infected patients receiving mucleoside analog treatment.
Antimicrob Agents Chemother, 54 (2010), pp. 1283-1289
[23.]
Z. Xiao, J. Xiao, Y. Jiang, et al.
A novel method based on ligase detection reaction for low abundant YIDD mutants detection in hepatitis B virus.
Hepatol Res, 34 (2006), pp. 150-155
[24.]
Y.Z. Wang, J.H. Xiao, L.H. Ruan, et al.
Detection of the rtA181V/T and rtN236T mutations associated with resistance to adefovir dipivoxil using a ligase detection reaction assay.
Clin Chim Act, 408 (2009), pp. 70-74
[25.]
M. Shi, Y. Zhang, Y.H. Zhu, et al.
Comparison of real-time PCR with the Cobas Amplicor for quantitation of hepatitis B virus DNA in serum samples.
World J Gastroenterol, 14 (2008), pp. 479-483
[26.]
B. Degertekin, M. Hussain, J. Tan, et al.
Sensitivity and accuracy of an updated line probe assay (HBV DR v.3) in detecting mutations associated with hepatitis B antiviral resistance.
J Hepatol, 49 (2009), pp. 695-701
[27.]
H.C. Lee, D.J. Suh, S.H. Ryu, et al.
Quantitative polymerase chain reaction assay for serum hepatitis B virus DNA as a predictive factor for post-treatment relapse after lamivudine induced hepatitis B e antigen loss or seroconverson.
Gut, 52 (2003), pp. 1779-1783
[28.]
Z. Wang, Y. Huang, S. Wen, et al.
Hepatitis B virus genotypes and subgenotypes in China.
Hepatol Res, 37 (2007), pp. S36-S41
[29.]
H.J. Yim, M. Hussain, Y. Liu, et al.
Evolution of multi-drug resistant hepatitis b virus during sequential therapy.
Hepatology, 44 (2006), pp. 703-712
[30.]
S. Locarnini.
Primary resistance, multidrug resistance and cross-resistance pathways in HBV as a consequence of treatment failure.
Hepatol Int, 2 (2008), pp. 147-151
Copyright © 2011. Elsevier Editora Ltda.. All rights reserved
